As of November 14, 2026, Vor Biopharma Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on July 7, 2026 (Form 8-K, July 7, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Vor Biopharma Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Vor Biopharma Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-07-07. Every row below is cited to the filing it comes from, and this page adds each new change as Vor Biopharma Inc. files it.
Layoffs on record: about 147 jobs, latest 2025-05-08 (layoff filings and notices).
Also on the record for Vor Biopharma Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 10.7% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Frazier Life Sciences Public Fund, L.P. | 4.2% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Venrock Healthcare Capital Partners III, L.P. | 9.9% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by Verve Capital Limited | 6.3% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 12% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G, by FMR LLC | 9.1% of the class | 5%+ stakes | Source |
| July 30, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.7% of the class | 5%+ stakes | Source |
| July 21, 2026 | Stake report, Schedule 13D/A, by RA Capital Management, L.P. | 19.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Venrock Healthcare Capital Partners III, L.P. | 9.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Verve Capital Limited | 9.3% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 3.2% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by Qiming Venture Partners VIII-HC, L.P. | 2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Vor Biopharma Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Vor Biopharma Inc. and the records around it.
Vor Biopharma Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Layoff notices May 2025
- Who owns it
Companies that share a holder
- 5AM Ventures VI, L.P. also filed stake reports on 2 other companies: CAMP4 THERAPEUTICS CORPORATION (Aug 2026), ARTIVA BIOTHERAPEUTICS, INC. (Aug 2026)
- ForGrowth III PA B.V. also filed stake reports on 4 other companies: Aura Biosciences, Inc. (Oct 2026), Crescent Biopharma, Inc. (Dec 2025), Astria Therapeutics, Inc. (Nov 2025)
- Great Point Partners, LLC also filed stake reports on 14 other companies: LeonaBio, Inc. (Nov 2026), Research Alliance Corporation III (Sep 2026), JATT III Acquisition Corp (Sep 2026)
Watch Vor Biopharma Inc.
Get an email when Vor Biopharma Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Vor Biopharma Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Vor Biopharma Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vor Biopharma Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 50 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-07 | Reported | not named in the filing | 8-K, 2026-07-07 |
New leaders reset buying decisions — get the Full Report on Vor Biopharma Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Vor Biopharma Inc., with the record behind each one.
Find candidates like senior executive at Vor Biopharma Inc.Every change, in the filing's words
Reported
(b) Resignation of Andrew Levin, M.D., Ph.D. as a Director On July 6, 2026, Andrew Levin, M.D., Ph.D., a member of the Board of Directors (the "Board") of Vor Biopharma Inc. (the "Company"), delivered his notice of resignation, effective immediately.
- Dr. Levin's decision to resign was not as a result of any disagreement with the Company.
- The Board thanks Dr. Levin for his service to the Company.
- (d) Appointment of David Zaccardelli, Pharm.D., as a Director On July 7, 2026, the Board appointed David Zaccardelli, Pharm.D. to the vacancy created by Dr. Levin's resignation, to serve on the Board as an independent Class II director until the Company's 2029 annual meeting of stockholders and until his successor is duly elected and qualified or his earlier resignation or removal.
- As of the date hereof, Dr. Zaccardelli has not been appointed to any committee of the Board.
- From 2020 to 2025, Dr. Zaccardelli served as President and Chief Executive Officer and as a director of Verona Pharma plc, a public pharmaceutical company developing ensifentrine for respiratory diseases, until its acquisition by Merck & Co., Inc. in October 2025.
- From 2018 to 2019, he served as President and Chief Executive Officer and as a director of Dova Pharmaceuticals, Inc., a public pharmaceutical company with the commercial product Doptelet for thrombocytopenia, which was acquired by Sobi in 2019.
- From 2016 to 2017, he served as Interim Chief Executive Officer and as a director of Cempra Pharmaceuticals, Inc., a public pharmaceutical company focused on antimicrobial therapeutics, which was acquired by Melinta Therapeutics LLC in 2017.
Tools for this story
Each opens in a new tab, filled in for Vor Biopharma Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
